Leading UK physicians and SMA advocacy groups have sent a strongly worded letter to Sir David Haslam, Chair of the National Institute of Health and Care Excellence (NICE), objecting to the proposed negative recommendation on nusinersen therapy.
In response to our queries Biogen has now sent us their take on the draft NICE guidance. Please read their Community Update below.
In the draft guidance issued today, the National Institute of Health and Care Excellence (NICE) decided NOT to recommend the use of nusinersen (Spinraza®) as an NHS treatment for spinal muscular atrophy in England and Wales.
In the next few weeks we are expecting the AveXis AVXS-101 trial to start enrolling. There will be two site centres here in the UK: Great Ormond Street Hospital for Children Contact : [email protected] The John Walton Muscular Dystrophy Research…
Please note this is not an affiliated Theraplay post, this is a review compiled by an owner of an adapted trike who has no association to the company and the views are their own. Adapted trikes are a great way…
It's August and its SMA Awareness Month. Please take time to view and share our video. Lets TreatSMA in all its forms, and lets get more treatments as soon as we can to help all.